Isomorphic Labs operates at the intersection of biotechnology, artificial intelligence, and pharmaceuticals, with a focus on accelerating drug discovery through advanced AI models and computational life sciences research. Given the company’s current Series B stage, European benchmarks (Q1 2026) for AI-enabled biotechnology and pharmaceutical businesses indicate valuation ranges of EV/Sales multiples of 3.61x – 4.99x, and EV/EBITDA multiples of 16.84x – 20.68x.
